2009 IoN News Archive
- Grant for research into new epilepsy treatments
- Professor Martin Rossor has been recognised by the The Alzheimer's Association
- Drug discovery collaboration on inclusion body myositis
- PDS awards Training Fellowship to Institute of Neurology researcher to understand how the brain controls Parkinson’s symptoms
- Alan Thompson to lead UCL Partners Neurological Disorders theme
- World MS Day - Wednesday 27th May - Global initiative to highlight Multiple Sclerosis
- Queen Square leads on new UK recommendations for bladder management which can dramatically improve quality of life in Multiple Sclerosis
- John Hardy most-cited Alzheimer's disease researcher in the UK
- Prestigious awards for Institute researchers
- Drug study offers hope for Alzheimer’s treatment
- Brain activity predicts our choices
- Professor George du Boulay CBE, FRCR, FRCP
- Brain awareness week: the impact of UCL research
- Parkinson's-linked mutation makes neurons vulnerable to calcium-induced death
- Second round of NIHR Senior Investigators announced
- 'Mind-Reading' Experiment Highlights How Brain Records Memories
- Anti-malaria drug does not appear to help with human prion diseases.
- UCL Partners is one of UK’s first Academic Health Science Centres
- "Opening doors for patients with MS"
- Are we as decisive as we think?
- "Magnets stop the nightmare of tinnitus, researchers say."
- Prestigious award for Professor Hugh Bostock
- Untangling the Brain
- Young UCL Investigator Award in neuroimaging techniques
- Brain disease "resistance gene" could offer insights into CJD
- Neurology: A Queen Square Textbook
- Headache: annual evidence update
- Roads closed for powerful MRI scanner delivery
- Long-term risks lower for surgical treatment of carotid stenosis
- Memorandum of collaboration signed
- Professor John Hardy joins the ranks of science greats
- Drug study offers hope for Alzheimer's treatment
- Prestigious award for Professor David Miller
- Magnets stop the nightmare of tinnitus, researchers say.
- Brain activity predicts our choices
- Jon Driver Award
- Professor Sander named recipient of the American Epilepsy Society 2009 Clinical Science Award
- Study highlights effect of brain waves on human behaviour
- New podcast describes the significance and impact of highly cited paper
- NIH Grant for research into inherited neuropathies
- How the brain knows a dog is a dog: concept acquisition in the human brain
- Prof Elizabeth Fisher elected member of the European Molecular Biology Organization (EMBO)
- Locating literacy in the brain
- Dopamine enhances expectation of pleasure in humans
- Queen Square scientists question memory theory
- IoN scientist to front Alzheimer’s Research Trust national appeal
- New doors open to the understanding of the origin of brain tumours
Published: Jul 8, 2013 2:00:00 PM
Published: Jul 5, 2013 5:29:00 PM
Published: Jun 5, 2013 3:54:00 PM
Published: Jun 5, 2013 2:24:00 PM
Grant for research into new epilepsy treatments
31 July 2009
Professor Matthew Walker (UCL Institute of Neurology) and Dr Robin Williams (Department of Biological Sciences at Royal Holloway, University of London) have been awarded £415,234 by the National Centre for Replacement, Refinement and Reduction to fund research into identifying new epilepsy treatments.
Epilepsy affects at least 40 million people worldwide, making it the most
common serious neurological condition in humans. To date there have been rapid
advancements in understanding how epilepsy occurs and in identifying new
treatments using animal experimentation, but Professor Walker and Dr Willliams
are aiming to advance our understanding of epilepsy using a different method of
Professor Walker said: “The approach we will be using is a novel and exciting way of identifying a whole new array of epilepsy treatments whilst minimising animal experimentation.”
Valproic acid (VPA) is one of the most widely prescribed drugs to treat epilepsy, but it is not clear how it works. Progress has already been made using the social amoeba Dictyostelium to identify bipolar disorder treatment targets in animals, and has improved our understanding of the cellular effects of the acid.
Dr Williams will use the amoeba Dictyostelium to probe further how VPA works
on fundamental cellular pathways and then to identify new potential treatments.
Professor Walker will then test these new treatments in the laboratory using in
vitro models of seizure activity to identify the treatments that are potentially
most effective in the treatment of epilepsy.
Image: The single-cell amoeba Dictyostelium can be used to replace animal cells in understanding the effects of epilepsy treatments
read more >> UCL News